RJFSA
AIMT

Raymond James Financial Services Advisors’s Aimmune Therapeutics AIMT Stock Holding History

Raymond James Financial Services Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,343
Closed -$173K – 3035
2020
Q2 		$173K Buy
+10,343
New +$176K ﹤0.01% 2534
2018
Q4 		– Sell
-7,525
Closed -$205K – 2919
2018
Q3 		$205K Hold
7,525
– – ﹤0.01% 2524
2018
Q2 		$202K Sell
7,525
-177
-2% -$5.42K ﹤0.01% 2485
2018
Q1 		$245K Buy
+7,702
New +$271K ﹤0.01% 2145

Other funds holding AIMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Raymond James Financial Services Advisors's AIMT Position: Q3 2020 in Review

Raymond James Financial Services Advisors sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 10,343 shares — an estimated $173K sold.

Raymond James Financial Services Advisors first reported a position in AIMT in Q1 2018 and held it in 4 quarters. The position peaked at $245K in Q1 2018. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

  • Raymond James Financial Services Advisors reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 10,343 Aimmune Therapeutics shares in Q3 2020, an estimated $173K.
  • Raymond James Financial Services Advisors first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 4 quarters.
  • Raymond James Financial Services Advisors's Aimmune Therapeutics position peaked at $245K in Q1 2018.
  • 188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2020, filed 4 Nov 2020.